Drugs / MVA/HIV62B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02852005 | Jan 2017 → Aug 2018 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA/HIV62B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02852005 ↗ |
| Modality | Vaccine | “MVA/HIV62B vaccine” NCT02852005 ↗ |
| Route | Intramuscular | “1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid” NCT02852005 ↗ |